Affimed NV Stock Discussion

$Affimed NV(AFMD.US)$ Upcoming Milestones: • Data readout from the 12 patients in cohorts 1 and 2 of the LuminICE-203 (AFM13 combination with AlloNK® cells) study in Q3 2024.
• ORR and PFS data from the 25 patients in the EGFRmut cohort of the AFM24-102 study in Q3 2024.
• ORR and PFS data from the 40 patients in the EGFRwt cohort of the AFM24-102 study in Q4 2024.

$Avalon GloboCare(ALBT.US)$ $Affimed NV(AFMD.US)$ $Structure Therapeutics(GPCR.US)$ $Finch Therapeutics(FNCH.US)$
On fire

Here are the levels to watch for continuation today.
Larger Image: tradingview.com...
$Affimed NV(AFMD.US)$

$Affimed NV(AFMD.US)$ out

$Affimed NV(AFMD.US)$
👉 GHOST  NET - DEMON TRAP - GAI WIX 👈👉 BUYERS  MUST SELL ALL AND DELETE NOW👈. 👎THEY BLOCK SHORT + (BID & ASK TOO FAR & UNDER $1 DELETE ), THEY ONLY TRAP STUPID INVESTORS BILLION OF DOLLARS A DAY 🗡👊💣👹💰
(STOK - PIK - LPA - DHAC - SMFL - SMMT - SRDX - VSTM - SMR - UVXY - AVTX - BTTR - DXYZ - GNLX - CZOO - MRUS - OKLO - AKAN - SWIN - IGMS - ARRY - MARA - CTNT - GTBP - EDBL - MTC - CAR - ARM - CVNA - SITM - NSP - POWL - AWIN - BIG - BMTX - DXYZ - DOGZ - HOLO - KOSS - MGNX - TTO...

$Affimed NV(AFMD.US)$
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Affimed has announced promising follow-up data for its AFM24 and atezolizumab combination therapy in heavily pretreated non-small cell lung cancer (NSCLC) patients. In the EGFR wild-type (EGFRwt) cohort, 4 out of 15 response-evaluable patients showed objective responses, with ...

$Affimed NV(AFMD.US)$ Affimed Says FDA Granted Fast Track Designation To Combination Of Its Innate Cell Engager AFM24 With Atezolizumab For EGFR Wild-Type Non-Small Cell Lung Cancer
Benzinga· 2 mins ago

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$  Phase 2
$Supernus Pharmaceuticals(SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$  Phase 2a
$MorphoSys(MOR.US)$  Phase 2
$Nuvation Bio(NUVB.US)$  Phase 2
$ALX Oncology(ALXO.US)$  Phase 2
$BioXcel Therapeutics(BTAI.US)$  Phase 2
$Purple Biotech(PPBT.US)$  Phase 2
$Arcus Biosciences(RCUS.US)$  Phase 2
$Medicenna Therapeutics(MDNAF.US)$  Phase 2b
$Affimed NV(AFMD.US)$  Phase 2
$Barinthus Biotherapeutics(BRNS.US)$  Phase 2b...

$Affimed NV(AFMD.US)$
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.